• Policy
• Enhertu passed the cancer dz review board after a retrial
• by Lee, Tak-Sun Jul 14, 2023 05:39am

• Policy
• HIRA declines NHIS and KPBMA's request
• by Lee, Tak-Sun Jul 14, 2023 05:39am

• Policy
• Approval of phase 3 for Retatrutide
• by Lee, Hye-Kyung Jul 14, 2023 05:38am

• Policy
• HIRA is reviewing reimb of Korea’s first donepezil 3mg
• by Lee, Tak-Sun Jul 14, 2023 05:38am

• Policy
• ‘Refer to Japan’s half-price policy for generic's price'
• by Lee, Tak-Sun Jul 13, 2023 05:35am

• Company
• "Cibinqo secures solid data in atopic dermatitis"
• by Jung, Sae-Im Jul 13, 2023 05:35am

• Policy
• Will the number of generics decrease?
• by Lee, Tak-Sun Jul 13, 2023 05:35am

• Company
• Schizophrenia drug Invega Hafyera lands in general hospitals
• by Eo, Yun-Ho Jul 13, 2023 05:35am

• Policy
• 2 Tylenol products stopped production will be decided in 2Q
• by Lee, Jeong-Hwan Jul 13, 2023 05:35am

• Company
• Samsung Biologics, cumulative order amt exceeded 2 trillion
• by Hwang, Jin-joon Jul 11, 2023 05:41am